Artichoke and Bergamot Phytosome
- Conditions
- Hypercholesterolemia
- Interventions
- Combination Product: PlaceboDietary Supplement: Combined Bergamot phytosome and Artichoke leaf dry extract
- Registration Number
- NCT04697121
- Lead Sponsor
- Azienda di Servizi alla Persona di Pavia
- Brief Summary
According to WHO data, about 50% of deaths each year are caused by cardiovascular disease. One of the strategies for prevention of cardiovascular diseases, in addition to a correct lifestyle, is to implement therapies that reduce the level of cholesterol in the blood and at the same time control the glycemic levels, which are closely related in the maintenance of metabolic homeostasis. The aim of this clinical study is to confirm the potential broader activity as hypocholesterolemic agent in bergamot poor-responders subjects with mild hypercholesterolemia. The study was a 8-week randomized double-blind placebo-controlled trial. Participants were randomized to either the supplement based on dry extract from artichoke leaf and bergamot phospholipid (31) or placebo arm (29).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- mild hypercholesterolemia (220 - 280 mg/dl)
- subjects were not taking any medication likely to affect lipid metabolism (such as statins)
- subjects were bergamot poor-responders
- liver, renal and thyroid diseases
- history of cardiovascular disease (CVD)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Combined Bergamot Phytosome and Artichoke leaf dry extract Combined Bergamot phytosome and Artichoke leaf dry extract 600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
- Primary Outcome Measures
Name Time Method Changes of lipid parameters Baseline / 30 days / 60 days Total cholesterol, LDL cholesterol, HDL cholesterol (mg/dl)
- Secondary Outcome Measures
Name Time Method Changes of lipid parameters Baseline / 30 days / 60 days apolipoprotein A, apolipoprotein B, triglycerides (mg/dl)
Changes of anthropometric measurements Baseline / 30 days / 60 days waist circumference (cm)
Changes of metabolic parameters Baseline / 30 days / 60 days Glycated Hemoglobin (percent)
Changes of body composition Baseline / 30 days / 60 days Fat mass (g), Fat Free Mass (g), Visceral Adipose Tissue (g)
Changes of safety parameters Baseline / 30 days / 60 days Creatinine (mg/dl)
Trial Locations
- Locations (1)
Azienda di Servizi alla Persona
🇮🇹Pavia, Italy